11th Feb 2008 07:01
GW Pharmaceuticals PLC11 February 2008 GW Pharmaceuticals to present at BIO CEO & Investor Conference Porton Down, UK, 11 February 2008: GW Pharmaceuticals plc (AIM: GWP) announcesthat its Managing Director, Justin Gover, will be presenting at the BIO CEO &Investor Conference in New York on Tuesday, February 12, 2008 at 2.45 pm EasternStandard Time (7.45 pm GMT). Investors may access a live webcast of the presentation at www.gwpharm.com onthe presentations page under the Investor Relations tab. An archived version ofthe presentation will be available later that day. Enquiries: GW Pharmaceuticals plc Today: +44 20 7831 3113Justin Gover, Managing Director Thereafter: + 44 1980 557000 Financial Dynamics (UK Tel: +44 20 7831 3113enquiries)David Yates, Ben Atwell Financial Dynamics (US Tel: +1 212 850 5600enquiries)Jonathan Birt, John Capodanno Notes to Editors About GW GW was founded in 1998 and listed on the AiM, a market of the London StockExchange, in June 2001. Operating under license from the UK Home Office, thecompany researches and develops cannabinoid pharmaceutical products for patientswho suffer from a range of serious ailments, in particular pain and otherneurological symptoms. GW has assembled a team of over 100 scientists withextensive experience in developing both plant-based prescription pharmaceuticalproducts and medicines containing controlled substances. GW occupies a worldleading position in cannabinoids and has developed an extensive internationalnetwork of the most prominent scientists in the field. This news release may contain forward-looking statements that reflect theGroup's current expectations regarding future events, including the clinicaldevelopment and regulatory clearance of the Group's products. Forward-lookingstatements involve risks and uncertainties. Actual events could differmaterially from those projected herein and depend on a number of factors,including (inter alia), the success of the Group's research strategies, theapplicability of the discoveries made therein, the successful and timelycompletion of clinical studies, including with respect to Sativex and theGroup's other products, the uncertainties related to the regulatory process, andthe acceptance of Sativex and other products by consumers and medicalprofessionals This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
GWP.L